Xpovio (selinexor) / Menarini, NeoPharm, Karyopharm, Jiangsu Hansoh Pharma, Antengene, FORUS Therap 
Welcome,         Profile    Billing    Logout  

51 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xpovio (selinexor) / Karyopharm
BOSTON, NCT03110562 / 2016-003957-14: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Checkmark From BOSTON trial for multiple myeloma
Jun 2021 - Jun 2021: From BOSTON trial for multiple myeloma
Checkmark Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
Checkmark Subgroup analysis data from BOSTON trial for r/r multiple myeloma at ASH 2020
More
Active, not recruiting
3
402
Europe, Canada, US, RoW
Selinexor, Bortezomib, Velcade®, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
02/20
09/23
2022-002540-42: A MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH ENDOMETRIAL CARCINOMA ENSAYO MULTICÉNTRICO DE SELINEXOR COMO TERAPIA DE MANTENIMIENTO PARA PACIENTES CON CÁNCER DE ENDOMETRIO

Not yet recruiting
3
220
Europe
Selinexor, KPT-330, Coated tablet, NEXPOVIO
Karyopharm Therapeutics Inc., KARYOPHARM THERAPEUTICS, INC., Karyopharm Therapeutics Inc.
Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with p53 wild-type, advanced or recurrent endometrial cancer Selinexor/placebo se administrará como terapia de mantenimiento después de la quimioterapia combinada para pacientes con cáncer de endometrio avanzado o recurrente de tipo p53 salvaje, Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with endometrial cancer Selinexor/placebo se administrará como terapia de mantenimiento después de la quimioterapia combinada para pacientes con cáncer de endometrio, Diseases [C] - Cancer [C04]
 
 
NCT06158841: Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, RoW
ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
01/28
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
3
150
RoW
SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
Antengene Corporation
Relapsed or Refractory Multiple Myeloma
07/24
10/24
SIENDO, NCT03555422 / 2017-000607-25: Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer []

Hourglass Sep 2023 - Oct 2023 : Presentation of data from SIENDO trial for TP53 wild-type endometrial cancer at ESGO 2023
Checkmark Subgroup analysis data from SIENDO trial for TP53 wild type endometrial cancer
Jan 2023 - Jan 2023: Subgroup analysis data from SIENDO trial for TP53 wild type endometrial cancer
Checkmark Data from SIENDO study in endometrial cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from SIENDO study in endometrial cancer at ASCO 2022
More
Active, not recruiting
3
263
Europe, Canada, US, RoW
Selinexor, Matching placebo for selinexor
Karyopharm Therapeutics Inc, Belgium and Luxembourg Gynaecological Oncology Group, North-Eastern German Society of Gynaecologic Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, GOG Foundation
Endometrial Cancer
01/22
12/25
NCT05726110: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
3
50
RoW
Selinexor, KPT-330, Homoharringtonine, HHT, Daunorubicin, DNR, Cytarabine, Ara-C, Granulocyte Colony-Stimulating Factor, G-CSF, Aclacinomycin, ACM
Shanxi Bethune Hospital, Antengene Corporation
Relapsed or Refractory Acute Myeloid Leukemia
12/24
12/24
XPORT-EC-042, NCT05611931: Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
SENTRY, NCT04562389: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/24
12/25
2014-001876-75: Study for patients with leukemic cells in their bone marrow

Ongoing
2
230
Europe
selinexor (20 mg), KPT-330, Tablet
HOVON Foundation, HOVON Foundation, Karyopharm Therapeutics
patients ≥ 66 years with: - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or - acute leukemia's of ambiguous lineage according to WHO 2008 or - a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R > 4.5, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04]
 
 
2020-006060-89: Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe)

Not yet recruiting
2
50
Europe
Selinexor, Revlimid, Bortezomib, Dexamethasone, Tablet, Capsule, hard, Injection, Selinexor, Revlimid, Bortezomib, Dexamethasone
Odense University Hospital, Nordic Myeloma Study Group
Multiple myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
NCT04768881: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Active, not recruiting
2
40
US
Selinexor, KPT-330, XPOVIO®, Pembrolizumab, KEYTRUDA®
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
09/23
01/24
SEARCH, NCT03992339: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
60
RoW
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle, Selinexor
Antengene Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
12/23
06/24
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
ESSENTIAL, NCT03627403: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Checkmark Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Nov 2022 - Nov 2022: Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Checkmark New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Nov 2021 - Nov 2021: New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Checkmark Data from ESSENTIAL trial for myelofibrosis
More
Active, not recruiting
2
17
US
Selinexor
University of Utah, Karyopharm Therapeutics Inc
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
08/23
03/25
SABLe, NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting
2
50
Europe
Selinexor 20 MG Oral Tablet, Xpovio, Bortezomib Injection, Velcade, Lenalidomide capsule, Revlimid, Dexamethasone Oral, Neofordex
Ida Bruun Kristensen, Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Multiple Myeloma
06/24
06/29
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Recruiting
2
141
Europe, RoW
Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
06/24
06/25
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
2
25
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
11/24
11/25
NCT05597345: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Recruiting
2
15
US
Selinexor
University of Rochester, Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
12/24
12/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
SELVEDge, NCT05530421: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Recruiting
2
33
US
Selinexor, Xpovio, Venetoclax, Venclexta, Venclyxto, Dexamethasone, Decadron, Ozurdex, Dexycu
University of Miami, Karyopharm Therapeutics Inc
Relapsed and Refractory Multiple Myeloma
03/26
03/28
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
US
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Recruiting
2
100
US
Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid
US Oncology Research, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
05/26
05/26
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Recruiting
2
35
US
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Data from SADAL trial in DLBCL
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT05983276: Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting
2
40
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Paclitaxel, Abraxane, Selinexor, Xpovio, Nexpovio
Loyola University, Karyopharm Therapeutics Inc
Ovarian Cancer
08/30
08/31
2017-004761-28: A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs) Estudio de Selinexor en combinación con imatinib en pacientes con tumores gastrointestinales (GISTs) metastasicos o irresecables

Not yet recruiting
1/2
41
Europe
Selinexor, Glivec, KTP-330, STI571, Coated tablet, Tablet, Glivec
Grupo Español de Investigación en Sarcomas, Karyopharm
Gastrointestinal stromal tumor (GIST) Tumor del estroma gastrointestinal, Gastrointestinal stromal tumor (GIST) is a rare cancer affecting the digestive tract or nearby structures within the abdomen. Tumor del estroma gastrointestinal es un cancer raro que afecta el tracto digestivo y otras estructuras adyacentes en el abdomen, Diseases [C] - Cancer [C04]
 
 
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT03095612: Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Terminated
1/2
41
US
Selinexor, KPT-330, Docetaxel
University of Texas Southwestern Medical Center, Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
11/22
03/23
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Recruiting
1/2
120
RoW
Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
03/25
03/25
NCT05577364: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Recruiting
1/2
54
RoW
Selinexor, exportin 1 (XPO1) inhibitor, R-CHOP Protocol, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Sun Yat-sen University, Fudan University, Antengene Corporation
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
12/24
02/26
NCT04856189: Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
1/2
12
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Mamta Parikh, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
05/24
05/24
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Checkmark Data from STOMP trial in combination with carfilzomib and dexamethasone for multiple myeloma at ASH 2020
More
Active, not recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Recruiting
1/2
84
RoW
ATG-010, Selinexor, Lenalidomide, Rituximab
Antengene Corporation
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
03/25
06/25
NCT05422027: Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Recruiting
1/2
42
RoW
Selinexor, ATG-010, Xpovio, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Dexamethasone Acetate
Xia Zhongjun, Antengene Corporation
Multiple Myeloma
06/25
12/25
NCT05698147: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Recruiting
1/2
30
RoW
Selinexor, ATG-010, Rituximab, RiTUXimab Injection, Methotrexate, MTX
Tong Chen, MD, Antengene Corporation
Central Nervous System Lymphoma
06/26
12/26
NCT02091245: Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Active, not recruiting
1
16
US
KPT-330, Selinexor
Dana-Farber Cancer Institute, William Lawrence and Blanche Hughes Foundation, Karyopharm Therapeutics Inc
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
02/18
12/24
NCT02120222: Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Completed
1
8
US
selinexor, CRM1 nuclear export inhibitor KPT-330, KPT-330, selective inhibitor of nuclear export KPT-330, SINE KPT-330, Correlative studies, pharmacological studies, pharmacokinetics, pharmacodynamics
Kari Kendra, Karyopharm Therapeutics Inc
Recurrent Melanoma
04/18
04/18
NCT02303392: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Active, not recruiting
1
34
US
Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis
Jennifer Woyach, Karyopharm Therapeutics Inc
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
04/22
12/22
NCT05201118: A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Recruiting
1
20
RoW
Selinexor, CT103A
Chunrui Li, Nanjing IASO Biotherapeutics Co.,Ltd
Extramedullary Multiple Myeloma
12/22
12/23
MATCH, NCT05354362: A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated
1
7
RoW
ATG-010 and ATG-008
Antengene Corporation
Relapsed/Refractory Diffuse Large B-cell Lymphoma
02/23
02/23
SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
42
US
Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples
St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
07/23
07/25
NCT03955783: Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Active, not recruiting
1
78
US
Venetoclax, Selinexor
Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie
Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
09/24
12/24
NCT04519476: Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Recruiting
1
22
US
Selinexor, KPT-330, Lenalidomide, Revlimid, Methylprednisolone, Medrol
Oncotherapeutics, Karyopharm Therapeutics Inc
Refractory Multiple Myeloma
12/23
12/23
KPT-IST-391, NCT06225310: A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Not yet recruiting
1
30
NA
Selinexor, Ruxolitinib, Methylprednisolone
Oncotherapeutics
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
04/27
05/27
SEATTLE, NCT05954780: Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
N/A
100
Europe
Selinexor
iOMEDICO AG, Stemline Switzerland GmbH, Climedo Health GmbH
Multiple Myeloma
09/25
09/25

Download Options